Tempus AI, Inc. (formerly Tempus Labs[1]) is an American health technology company[2] founded in 2015 by Eric Lefkofsky in Chicago, Illinois.[3] It was established by Lefkofsky soon after his wife was diagnosed with breast cancer.[4] Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics,[5] for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."[6][7]
Tempus does genome sequencing and precision medicine, including diagnostics, primarily for cancer patients, as well as for cardiology patients, radiology, and pharmacogenomic testing for patients with depression.[8] It is headquartered in Chicago.[9]
Tempus investors include SoftBank Group, Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, Google LLC, and others.[10]
In June 2024, Tempus and SoftBank formed an AI healthcare joint venture in Japan called SB Tempus with a plan to develop personalized treatment recommendations by analyzing medical data with AI.[11][12] In November that year, Tempus agreed to acquire California-based genetic testing company Ambry Genetics for $600 million in a cash-and-stock deal.[13]
The company's advisory board includes Jennifer Doudna and Scott Gottlieb.[1] As of 2024, Tempus employs around 2,300 people.[14]
